Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a potent, selective inhibitor of P-glycoprotein (P-gp), an ATP-dependent efflux pump that drives multidrug resistance (MDR) in cancer. At low micromolar concentrations, Zosuquidar restores drug sensitivity in P-gp–overexpressing tumor cell lines and enhances the efficacy of chemotherapeutics in animal models (APExBIO). The compound acts by competitively inhibiting P-gp substrate binding, without significantly altering the pharmacokinetics of co-administered drugs (Sun et al., 2025). Clinical trials in non-Hodgkin’s lymphoma and advanced solid tumors show effective P-gp inhibition with minimal toxicity. Zosuquidar is supplied as a trihydrochloride salt, soluble in DMSO, and intended for research use only. This article extends previous lab guidance by synthesizing mechanistic, pharmacokinetic, and translational findings for precision MDR research.

Biological Rationale

P-glycoprotein (P-gp, also known as ABCB1 or MDR1) is a 170-kDa ATP-binding cassette (ABC) transporter. P-gp is expressed in the plasma membranes of excretory and barrier tissues, including the brain, liver, small intestine, and various tumor cells (Sun et al., 2025). Its physiological role is to protect tissues by exporting xenobiotics and metabolic waste. In cancer, overexpression of P-gp leads to active efflux of structurally diverse chemotherapeutic agents, reducing their intracellular concentrations and efficacy. This process underlies clinical multidrug resistance (MDR) phenomena, most commonly in acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and solid tumors (see also: advanced approaches to P-gp inhibition). Inhibiting P-gp is a validated strategy to restore chemosensitivity.

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl is a third-generation, non-transported, and highly selective P-gp inhibitor (APExBIO). It binds competitively to the drug-binding pocket of P-gp, preventing the efflux of cytotoxic drugs such as vinblastine, doxorubicin, paclitaxel, and etoposide. Unlike earlier inhibitors, Zosuquidar has minimal activity against other ABC transporters (e.g., MRP1, BCRP) and does not itself undergo significant P-gp–mediated efflux. Mechanistic studies using photoaffinity labeling and substrate binding assays confirm that Zosuquidar blocks both substrate recognition and ATPase activity of P-gp (Sun et al., 2025). This results in increased intracellular drug accumulation and restored cytotoxicity in MDR cell models.

Evidence & Benchmarks

• In vitro, Zosuquidar at 0.1 μM fully restores sensitivity to vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp–overexpressing leukemia cell lines (Sun et al., 2025, https://doi.org/10.1016/j.biopha.2025.118665).
• In vivo, co-administration of Zosuquidar enhances the antitumor activity of chemotherapeutics in murine leukemia and human lung carcinoma xenografts without altering the pharmacokinetics of the drugs (Sun et al., 2025, https://doi.org/10.1016/j.biopha.2025.118665).
• Phase I/II clinical trials show that Zosuquidar combined with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in non-Hodgkin’s lymphoma leads to effective P-gp inhibition and minimal toxicity (APExBIO, https://www.apexbt.com/zosuquidar.html).
• Zosuquidar does not significantly inhibit hepatic cytochrome P450s or alter the pharmacokinetics of co-administered drugs in preclinical studies (Sun et al., 2025, https://doi.org/10.1016/j.biopha.2025.118665).
• Photoaffinity labeling assays show that Zosuquidar inhibits P-gp substrate binding with high specificity (APExBIO, https://www.apexbt.com/zosuquidar.html).
• For an in-depth mechanistic analysis, see Strategic Inhibition of P-glycoprotein: Zosuquidar (LY335979) 3HCl, which this article clarifies by detailing in vitro/in vivo benchmarks and clinical translation.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is used in research to reverse P-gp–mediated multidrug resistance in cancer models, particularly in AML, non-Hodgkin’s lymphoma, and solid tumors (APExBIO). It is applied in P-glycoprotein inhibition assays, drug sensitization protocols, and preclinical pharmacokinetic studies. Zosuquidar is not a diagnostic or therapeutic agent for human use outside research settings.

Common Pitfalls or Misconceptions

• Zosuquidar is ineffective against multidrug resistance mediated by non-P-gp efflux pumps (e.g., MRP1, BCRP).
• It does not restore sensitivity if resistance is due to drug metabolism or target mutations, not efflux.
• Long-term storage of Zosuquidar solutions is not recommended due to potential degradation; always prepare fresh stocks.
• Zosuquidar does not significantly alter hepatic CYP450 activity, but interactions with non-P-gp substrates should be ruled out experimentally.
• Clinical efficacy is context-dependent and may not extend to all tumor types or drug regimens.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl is supplied as a trihydrochloride salt (C32H31F2N3O2·3HCl) with a molecular weight of 527.6 g/mol. The product (SKU: A3956) is available from APExBIO here. It is soluble in DMSO at >20 mg/mL. Recommended storage is at -20°C in a desiccated environment. Prepare working solutions fresh before use in cell-based or in vivo assays. For reversal of MDR in vitro, 0.1–1 μM is standard; for animal studies, dosing regimens must be optimized for the model and endpoint. For protocol design and troubleshooting, see our protocol-driven guide, which this article updates with recent pharmacokinetic findings.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a validated, highly selective P-glycoprotein inhibitor that enables researchers to reverse MDR reliably in controlled settings. Its lack of significant off-target effects or CYP450 interactions makes it suitable for in vitro and in vivo translational research. Ongoing advances in transporter biology and pharmacokinetics may further refine its application, especially for personalized anticancer drug regimens. For advanced strategies and clinical perspectives, see this systems-level analysis, which this article extends by providing practical workflow integration details.